Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Zhimeng Bio Starts US Trials for Novel Epilepsy Therapy

publication date: May 12, 2022

Shanghai Zhimeng Biopharma has dosed the first participant in a US Phase I study of its novel small-molecule KCNQ2/3 selective opener for refractory epilepsy. Epilepsy is an imbalance between neuronal excitation and inhibition, which is caused by dysfunction in ion channels, especially the potassium (K+) channels. Zhimeng’s CB03 is a new generation of KCNQ2/3 potassium channel opener with improved chemical and metabolic stability, antiepileptic activity and safety. Its highly selective ion channel targeting is designed to avoid the side effects of previous ion channel drugs. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Singapore and Digital
April 26-27, 2023
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China